Dual-action Nanoplatform with a Synergetic Strategy to Promote Oxygen Accumulation for Enhanced Photodynamic Therapy Against Hypoxic Tumors

Chunling Ren,Xiao Xu,Dan Yan,Mengzhen Gu,Jinghan Zhang,Haili Zhang,Chao Han,Lingyi Kong
DOI: https://doi.org/10.1016/j.actbio.2022.04.035
IF: 10.633
2022-01-01
Acta Biomaterialia
Abstract:With the development of redox-related therapy modalities in cancer therapy, photodynamic therapy (PDT) has gradually become the most widely used type in the clinic. However, the hypoxic tumor microenvironment restricted the curative effect of PDT. Here, a strategic hypoxia relief nanodrug delivery system (SHRN) with a synergetic strategy was designed to alleviate tumor hypoxia on the basis of PDT. Specifically, the oxygen producer MnO2, oxygen consumption inhibitor atovaquone (ATO) and photosensitizer hypericin (HY) were loaded in SHRN. MnO2 reacted with excess H2O2 in the tumor microenvironment to increase oxygen generation, while ATO inhibited electron transfer in the aerobic respiratory chain to decrease oxygen consumption. Then, HY utilized this sufficient oxygen to produce ROS under irradiation to enhance the PDT effect. In vitro and in vivo assays confirmed that SHRN exhibits powerful and overall antitumor PDT effects. This formulation may provide an alternative strategy for the development of PDT effects in hypoxic tumor microenvironments. Statement of significance We constructed a strategic hypoxia relief nanodrug delivery system (SHRN) with a synergetic strategy to alleviate tumor hypoxia on the basis of photodynamic therapy (PDT). This work uniquely aimed at not only increased O-2 generation in hypoxic tumor microenvironment but also reduced O-2 consumption. Moreover, we designed a nanodrug delivery system to enhance the tumor permeability of SHRN. In vitro and in vivo assays all confirmed that SHRN exhibited powerful and overall antitumor effects. This formulation may provide an alternative strategy for the development of the PDT effect in hypoxic solid tumor.(c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?